Clinical Trial

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

Study acronym: NETOSE
Recruiting
View on ClinicalTrials.gov →
Summary
Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis. The loss of self-tolerance is believed to be caused by the dysregulation of both innate and adaptive immune systems and may involve Reactive Oxygen Species (ROS). Neutrophils are potent producers of ROS and may play a role in endothelial cells and fibrobasts dysfunction, as in autoantibodies generation. However, their role in SSC pathogenesis remains to be determined. Recent studies discovered abnormal regulation of Neutrophil Extracellular Traps (NETs) in other auto-immune diseases such as Systemic Lupus Erythematosus (SLE). NETs are web-like structures composed of chromatin backbones and granular molecules. They are released by activated neutrophils through a process called "NETosis". Nets were first described in 2004 as a novel host defense mechanism to trap and kill foreign pathogens. Recent evidence shows that NETs also participate in the pathogenesis of a variety of inflammatory and autoimmune diseases, including SLE. The investigators recently highlighted this phenomenon in SSc, especially in patients with vascular complications and/or at a early stage of the disease. The investigators will now explore the factors implicated in this dysregulation of NETosis in SSc.
Trial Details
NCT Number NCT06462768
Lead Sponsor CHU de Reims
Conditions Systemic Sclerosis, Other Connective Tissue Disease, Systemic Lupus Erythematosus, Dermatomyositis, ANCA Associated Vasculitis
Enrollment 260 participants
Start Date 2023-11-27
Primary Completion 2028-10-27 (estimated)
Study Completion 2029-04-27 (estimated)
Updated on ClinicalTrials.gov 2024-06-17